Investigating Thromboxane Function in Women With Endometriosis
The Role of Thomboxane A2 and it's Receptor in Vascular Regulation in Women With Endometriosis
This study is testing whether taking aspirin can help women with endometriosis have better blood flow and pain responses compared to healthy women.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 96 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | Penn State University Academic / other |
| Locations | 1 site (University Park, Pennsylvania) |
| Trial ID | NCT05962034 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare neurovascular regulation between women with endometriosis and healthy women. Participants will take either aspirin or a placebo and undergo various tests, including hand grip exercises and cold pressor tests, to assess blood pressure and pain responses. The study will also evaluate platelet activity and the role of thromboxane A2 in endothelial dysfunction associated with endometriosis. By analyzing these factors, researchers hope to uncover differences in cardiovascular responses between the two groups.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18-45, with or without a diagnosis of endometriosis.
Not a fit: Patients who are currently pregnant, breastfeeding, or have existing cardiovascular diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in women with endometriosis.
How similar studies have performed: While there is existing research on endometriosis and cardiovascular health, this specific investigation into thromboxane function is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Born with a uterus * 18-45 years old * With and without endometriosis Exclusion Criteria: * Currently pregnant or breastfeeding * Diagnosed cardiovascular disease * BMI over 35 * Nicotine use (e.g., smoking, chewing tobacco, vaping, etc.) * Currently using hormone replacement therapy (or have used within previous 6 months) * Known skin allergies or current rash, skin disease, disorders of pigmentation * Diabetes * Renal disease, renal artery stenosis, renal impairment * Liver disease * Stage II Hypertension (blood pressure \>140/\>90 mmHg) * Hypotension (blood pressure \< 90/60 mmHg) * Raynaud's syndrome * Any current medications which could conceivably alter cardiovascular responses (e.g. antihypertension medication, diuretic, digoxin) * Allergy or hypersensitivity to investigational agents * Immunosuppressed/immunocompromised
Where this trial is running
University Park, Pennsylvania
- Noll Laboratory — University Park, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Lacy Alexander, Ph.D.
- Email: lma191@psu.edu
- Phone: 8148671781
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.